Abstract
Uncertainty concerning pharmaceutical industry R & D continues to grow, which is making it increasingly difficult to introduce new drugs to market. This paper presents a hypothetical exploratory analysis of factors that affect the translation of new drug discoveries to clinical research.
The first factor is the organizational capability to maintain propriety throughout the drug development process, either through technological superiority or the accumulation of organizational capability. Second, Patent protection is important in order to avoid the follow from other companies. Third, within the pharmaceutical industry, technological superiority is more important than accumulating organizational capability as a factor for promoting protection through patents. However, it was shown that the accumulation of organizational capability affected organizational capability to build technological superiority.
These findings point to future research directions that incorporate cross-sectional data across multiple industries. Moreover, further studies could explore in detail how accumulating organizational capability builds technological superiority. There are some variables that have not been considered in this study.
